Heart failure drug treatment: the fantastic four | European Heart ...
2021年1月11日 · Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with combination of several drugs as the cornerstone for symptomatic and prognostic improvement in all patients. 1 , 2 Drug therapies such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor/neprilysin inhibitors (ARNIs; sacubitril/valsartan ...
Heart failure drug treatment: the fantastic four - PMC
Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with combination of several drugs as the cornerstone for symptomatic and prognostic improvement in all patients. 1,2 Drug therapies such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor/neprilysin inhibitors (ARNIs; sacubitril/valsartan), ...
Fantastic Four - Journal of Cardiac Failure
With its ability to reduce blood pressure, body mass index, and glycated haemoglobin (HbA1c), its addition along with the other guideline-directed management and therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) will require adjustment of …
Fighting heart failure with ‘Fantastic Four,’ new guidelines
2023年2月15日 · SGLT2 inhibitors are now recommended for people with heart failure with reduced ejection fraction (HFrEF), regardless of whether they have Type 2 diabetes. This recommendation creates a “Fantastic Four” of effective medications to treat patients with HFrEF.
Heart failure drug treatment: The fantastic four - ResearchGate
2021年1月14日 · The following four basic HF drugs have been widely recognized as the “Fantastic Four”: beta-adrenergic blocking agents, mineralocorticoid receptor antagonists (MRA), sodium glucose...
Heart failure drug treatment: the fantastic four. - Europe PMC
2021年2月1日 · According to an elegant analysis by Vaduganathan et al. (2020) this four-drug strategy in a 55-year-old HFrEF patient provides an additional gain of 8.3 years free from cardiovascular death or first heart failure hospital admission, and 6.3 additional years of survival compared with the often used conventional combination of an ACE inhibitor ...
ESC 365 - Heart failure drug treatment: the fantastic four
2021年1月11日 · Access European Heart Journal article on CARDIOVASCULAR PHARMACOLOGY,HEART FAILURE,Chronic Heart Failure,Pharmacology and …
Medical Treatment in Heart Failure with Reduced Ejection ... - MDPI
2023年5月24日 · In heart failure (HF) with reduced ejection fraction (HFrEF), four classes of drugs, the so-called fantastic four, also known as β-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), and the most recent Sodium–Glucose Co-Transporters 2 ...
According to an elegant analysis by Vaduganathan et al. (2020) this four-drug strategy in a 55-year-old HFrEF patient provides an add-itional gain of 8.3 years free from cardiovascular death or first heart failure hospital admission, and 6.3 additional years of survival com-pared with the often used conventional combination of an ACE in-hibitor ...
Heart failure drug treatment: the fantastic four - Semantic …
2021年1月11日 · Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril–valsartan therapy led to a greater reduction in the N‐terminal pro–B‐type natriuretic peptide concentration than enalapril therapy.